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THE USE OF M&S FOR DOSE-REGIMEN SELECTION
Optimal dose-regimen selection attempts to select a drug 
input profile that offers the best benefit/risk ratio for a given 
indication in a given population. Knowledge of the dose– 
exposure–response relationship is the key aspect for rational 
dose selection. The dose–exposure–response relationship 
is driven by the underlying pharmacology that characterizes 
the causal chain between administration of the dose and 
the observation of the response. Depending on the devel-
opmental state of a compound, response measures can be, 
e.g., measures for receptor occupancy, biomarker measure-
ments indicating target engagement, surrogate end points, 
or clinical end points for efficacy or safety. Consideration 
of these pharmacology principles represents a first step in 
developing a rational approach to dose–response charac-
terization. Mathematical models that allow integrating the 
available data under consideration of the pharmacological 
principles described above are well suited to characterize the 
dose– exposure–response relationship and predict a dosing 
regimen that offers the best benefit/risk ratio for the patient. 
A more accurate prediction of the right dose might lead to 
more efficient trials with a consequent saving in patients and 
costs (Table 1, IP1).
Although this approach is very attractive and was already 
often successfully used in the past,1,2 its application in 
clinical development is sometimes limited for various rea-
sons. On the one hand, traditional dose ranging studies 
required by regulatory authorities, which involves pairwise 
comparisons, may not allow the elucidation of the nature 
of the dose–response relationship. On the other hand, the 
unavailability of suitable biomarkers, nonsensitive clinical 
end points, highly variable disease, or the absence of a 
causal relationship hamper the conventional dose-finding 
approach as well as the modeling approach. Moreover, one 
of the main reasons for not applying models more exten-
sively for dose-regimen selection processes is the concern 
regarding model bias and hypotheses, i.e., doubts that the 
model is a correct representation of the system (Table 1, 
RP1, CS1).
Despite these concerns and limitations, all participants of 
the workshop agreed that an M&S approach to dose-regimen 
selection may be helpful in providing insight into the “true” 
dose–exposure response relationship. Exploring pharma-
cokinetic–pharmacodynamic relationships in deeper detail 
by M&S has been helpful in regulatory decision making on 
the dose in the past (3,4, Table 1, RP1, CS3), especially in 
situations in which parallel studies did not provide a clear dis-
tinction between different dose levels.
In general, regulators will be more willing to accept dose-
regimen finding by M&S in situations at which a limited num-
ber of patients are available or a condition is difficult to study 
(e.g., for orphan indications, pediatrics, or elderly with renal 
insufficiency), or if pharmacokinetic–pharmacodynamic rela-
tionships are very clear or straightforward (e.g., line exten-
sions of accepted products, anti-infectives, or antidote 
drugs). Study designs that allow a better understanding of the 
pharmacokinetic–pharmacodynamic relationship are encour-
aged (Table 1, CS2); however, usually some Phase II parallel 
dose-finding studies are still required for new drugs.
From an industry perspective, which was confirmed by some 
regulators, the limited exposure of regulators to these M&S 
approaches and the limited experience with regard to evalu-
ating the results hinder a more definite answer from regula-
tors regarding what is expected from industry and give rise to 
variable responses for the modeling parts in submissions. On 
one hand, this lack of predictable regulatory acceptance hin-
ders the further implementation of M&S-driven dose- regimen 
selection approaches in the pharmaceutical industry. On the 
other hand, M&S scientists of companies might have to deal 
with skepticism regarding M&S approaches within their own 
organization. Some decisions actually based on M&S may 
not end up in the clinical overview, a key document for regula-
tory assessment, thereby reducing the chance that the mod-
els are indeed considered pivotal in the process of regulatory 
assessment.
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THE USE OF M&S TO REGISTER A DOSING REGIMEN 
WITHOUT THE NEED FOR A SPECIFIC STUDY
For a specific compound, it might not be possible to provide 
comprehensive safety and efficacy data for each (sub)popula-
tion of interest or specific therapy condition due to ethical con-
siderations and feasibility of studies. In such situations, M&S 
approaches could be used to integrate suitable data (e.g., 
across studies or inclusion of in vitro data) and give the pos-
sibility to simulate (investigate) situations that cannot be tested 
or should be avoided. This together with reasonable assump-
tions might provide enough evidence for efficacy/safety with-
out the need for a separate study (Table 1, IP2, RP2).
The participants were, in general, more comfortable 
using a modeling approach for interpolation rather than 
extrapolation.5 With respect to pharmacokinetics and 
 pharmacokinetic–pharmacodynamic relationships, nowa-
days, interpolation is quite commonly used (e.g., when 
estimating exposure in case of renal or hepatic impairment 
(Table 1, CS4)). However, confidence in extrapolation can 
be increased by the use of external data, prior information, 
mechanistic understanding and at least some sparse data. 
From a regulatory perspective, experience with translational 
M&S, e.g., extrapolation of in silico drug–drug interaction 
data to the actual clinical situation seems promising; however, 
current regulatory experience leading to dose advice on Data 
Documentation Initiatives is limited (Table 1, CS5).
One important question was how M&S can be used to 
improve the approach to QT prolongation risk. Data were pre-
sented (Table 1, RP2, CS6) that showed how the totality of 
evidence significantly improves the negative and positive pre-
dictive values of the characterization of QT vs. using any one 
QT study in isolation.6,7 Characterization in this case refers 
to the ability of the combined assays to appropriately iden-
tify the potential risk of a clinically significant drug-induced 
change in the QT interval.
Potential hurdles could be inconsistent preclinical or clini-
cal data acquisition/analysis. Two main approaches could be 
identified: empirical approach—collect data set demonstrat-
ing ability of Phase 1 to predict TQT. The empirical approach 
simply follows a retrospective (or prospective) correlation of 
early phase data to TQT studies. This provides no incentive 
for companies to provide improved data in preclinical or early 
clinical studies; or incentive approach—written guidance that 
allows sponsors to delay TQT until Phase 3, or omit TQT alto-
gether, if appropriate preclinical or clinical data are acquired 
and used for prospective predictions of QT liability. To be 
noted, in Europe, this decision is the local ethical committees’ 
responsibility, as the European Medicines Agency does not 
decide on initiation of Phase III trials. An incentive approach 
Table 1 Presentations breakout session 2: modeling and simulation in clinical pharmacology and dose finding
Title Presenter Link to presentation
Dose–exposure–response relationships: the basis 
of effective dose-regimen selection—industry 
perspective (IP1)
Michael Lobby (Novartis)/Peter Miligan 
(Pfizer)
http://www.ema.europa.eu/docs/en_GB/document_library/
Presentation/2011/11/WC500118276.pdf
Dose–concentration–response–relationship—
regulatory perspective (RP1)
Elisabeth Rook (Medicine Evaluation 
Board)
http://www.ema.europa.eu/docs/en_GB/document_library/
Presentation/2011/11/WC500118275.pdf
Dose finding under model uncertainty—a case study 
based on a multiregional clinical trial (CS1)
Chyi-Hung Hsu (Johnson & Johnson) http://www.ema.europa.eu/docs/en_GB/document_library/
Presentation/2011/11/WC500118274.pdf
Design of a model-based dose-finding study in 
diabetes (CS2)
Marie Sandstrom (Astra Zeneca)/Sofia 
Friberg Hietala (Astra Zeneca)
http://www.ema.europa.eu/docs/en_GB/document_library/
Presentation/2011/11/WC500118277.pdf
Improvement of clinical benefit for a subgroup of 
pediatric sJIA patients utilizing model-based dose 
adjustment optimization (CS3)
Nicolas Frey (Hoffmann-La Roche) http://www.ema.europa.eu/docs/en_GB/document_library/
Presentation/2012/04/WC500126726.pdf
The integration of data (e.g., across studies or clinical 
and in vitro data) using modeling and simulation 
along with reasonable assumptions can provide 
evidence for evaluation of efficacy/safety risks 
without the need for a separate study—industry 
perspective (IP2)
Charles Benson (Eli Lilly) http://www.ema.europa.eu/docs/en_GB/document_library/
Presentation/2011/11/WC500118278.pdf
Integration of data using modeling and simulation 
can provide evidence for evaluation of efficacy-
safety risks without the need for a separate  
study—regulatory perspective (RP2)
Marc Maliepaard (Medicine Evaluation 
Board)
http://www.ema.europa.eu/docs/en_GB/document_library/
Presentation/2011/11/WC500118279.pdf
Modeling and simulation for dose adjustment in 
renally impaired patients (CS4)
Monica Edholm (European Medicines 
Agency, EMA)
http://www.ema.europa.eu/docs/en_GB/document_library/
Presentation/2011/11/WC500118280.pdf
Modeling of drug-interaction mechanism and 
estimation of drug interaction in patients with renal 
impairment (CS5)
Monica Edholm (EMA) http://www.ema.europa.eu/docs/en_GB/document_library/
Presentation/2011/11/WC500118280.pdf
Assessing the probability of drug-induced  
QTc-interval prolongation during early clinical  
drug development (CS6)
Oscar Della Pasqua (Glaxo SmithKline) http://www.ema.europa.eu/docs/en_GB/document_library/
Presentation/2011/11/WC500118281.pdf
The framework of this session was “use of modeling and simulation with existing information (data, physiological/mechanistic knowledge) and reasonable 
assumptions will allow for improvements and efficiency in informed decision making to improve the outcomes for patient safety and efficacy in the clinical 
pharmacology arena.” Organizing committee: L.A., Norbert Benda, C.B., M.M., France Mentré, Krishna Prasad, Amin Rostami, E.R., and A.S.
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rewards companies that design studies optimally and per-
form and evaluate them excellently with the opportunity to 
avoid the TQT study.
It might be necessary to perform first a “totality of evidence” 
approach to QT assessment to predict reliably negative and 
positive early phase data before an incentive approach can 
be taken. To convince the regulators completely, a number of 
“totality of evidence” data sets need to be provided to them for 
thorough evaluation. To achieve this, possibilities of precom-
petitive sharing of data should be evaluated.8 For example, a 
proposal is currently being put forward for a study of a set of 
well-characterized compounds to describe the ability of non-
clinical and early clinical assays to find (or not find) a QT sig-
nal at the threshold of regulatory interest. If this approach is 
successful, regulatory agencies may agree that if nonclinical 
and early clinical data are generated in a similar fashion and 
rule out significant risk, a TQT study will not be required.
In general, it can be concluded that the acceptability of 
M&S approaches instead of observational data for registra-
tion of a dosing regimen in an untested population/condition 
is difficult to state in general terms as it is influenced by many 
factors. Important requirements will be that the clinical and 
pharmacological assumptions of the model are adequately 
supported by both empirical evidence and the underlying 
mechanistic understanding; in addition, a suitable risk mitiga-
tion strategy should be implemented.
For all kinds of M&S analyses discussed in this break out 
session, it can be stated that key points for appropriate and 
efficient regulatory assessment are clear communication, 
informing assessors adequately on the justification of the 
model, and on assumptions made by the modelers. Ade-
quate validation, with an assessment of robustness (sensi-
tivity analysis) and predictive performance of the model is a 
prerequisite for regulatory acceptance.
COMMON OBJECTIvES AND PROPOSED NEXT STEPS
Industry, regulators, and academia were aligned in that M&S 
is an important tool to support dose-regimen selection for 
a target population as well as to dosing recommendations 
for an untested population/clinical condition (see Table 2 in 
ref. 9). Although it will be very difficult to come up with an uni-
versally applicable and definite criteria when and how these 
approaches are accepted, all participants agreed that this 
can be facilitated by developing a framework for acceptance. 
As a first step, the development of a guideline that endorses 
the use of M&S in general was proposed, or/and an update 
of relevant documents such as the International Conference 
on Harmonisation of Technical Requirements for Registration 
of Pharmaceuticals for Human Use dose-finding guideline10 
were found crucial to further advance the role of M&S in clini-
cal development. In the development of such documents, it 
should be noted that the guidelines should not be too restric-
tive so as to hinder this innovative field.
With regard to QT prolongation, it should be defined what 
has to be done so that a combined “totality of evidence” 
approach to QT assessment can be applied and accepted for 
delay or as a replacement of a TQT study (e.g., precompeti-
tive sharing of data, combination with other initiatives).
In addition, interaction between regulators and industry 
regarding M&S approaches should be intensified using either 
already existing possibilities (e.g., project-specific scientific 
advice, innovation task force, or qualification process) and/
or new ways that can be discussed, e.g., at further European 
Medicines Agency/European Federation of Pharmaceutical 
Industries and Associations workshops. As a third objective, 
additional training of assessors to allow a comprehensive 
evaluation of the M&S approaches/results was identified as 
an important factor to promote these approaches.
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